cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.7926136
title: SpliceAI_rocksdb_hg38_chr6

description: SpliceAI RocksDB for chromosome 6 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926133
title: SpliceAI_rocksdb_hg38_chr4

description: SpliceAI RocksDB for chromosome 4 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926132
title: SpliceAI_rocksdb_hg38_chr4

description: SpliceAI RocksDB for chromosome 4 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926124
title: SpliceAI_rocksdb_hg38_chr3

description: SpliceAI RocksDB for chromosome 3 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926123
title: SpliceAI_rocksdb_hg38_chr3

description: SpliceAI RocksDB for chromosome 3 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926108
title: SpliceAI_rocksdb_hg38_chr2

description: SpliceAI RocksDB for chromosome 2 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926107
title: SpliceAI_rocksdb_hg38_chr2

description: SpliceAI RocksDB for chromosome 2 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926110
title: SpliceAI_rocksdb_hg38_chr1

description: SpliceAI RocksDB for chromosome 1 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926109
title: SpliceAI_rocksdb_hg38_chr1

description: SpliceAI RocksDB for chromosome 1 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.6084/m9.figshare.22952348.v2
title: S2_Appendix.sav

description: This is minimal data underlying the findings described in the manuscript.
DOI: 10.6084/m9.figshare.22952348
title: S1 Dataset

description: <strong>Deidentified dataset.</strong>
DOI: 10.6084/m9.figshare.22952348.v4
title: S1 Dataset

description: <strong>Deidentified dataset.</strong>
DOI: 10.6084/m9.figshare.22952348.v3
title: <strong>S1 Dataset</strong>

description: <strong>Deidentified dataset.</strong>
DOI: 10.6084/m9.figshare.22953908
title: Supplementary Material for: Long-term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

description: ASPIRE, a three-part, international, phase II trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia, and grade 4 thrombocytopenia (&lt;25 × 109 platelets/L). Approximately 30–65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.
DOI: 10.6084/m9.figshare.22953908.v1
title: Supplementary Material for: Long-term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

description: ASPIRE, a three-part, international, phase II trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia, and grade 4 thrombocytopenia (&lt;25 × 109 platelets/L). Approximately 30–65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.
DOI: 10.6084/m9.figshare.22954019
title: Supplementary Material for: Long-term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

description: ASPIRE, a three-part, international, phase II trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia, and grade 4 thrombocytopenia (&lt;25 × 109 platelets/L). Approximately 30–65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.
DOI: 10.6084/m9.figshare.22954019.v1
title: Supplementary Material for: Long-term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

description: ASPIRE, a three-part, international, phase II trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia, and grade 4 thrombocytopenia (&lt;25 × 109 platelets/L). Approximately 30–65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.
DOI: 10.15151/esrf-es-1180252633
title: Cavity formation upon loading and unloading in cross-linked rubber nanocomposites

description: The primary goal of this proposal is to study the effect of polymer blend morphology on cavity formation by varying the type of polymers in a blend and also the blend ratio. Cavities will be induced both in the bulk of the material by fatigue and locally by tensile deformation. Moreover, the proposal aims to understand how filler dispersion in such complex systems affects cavity formation mechanisms. For this, we will study the effect of the filler micro-dispersion in polymer blends on the molecular damage mechanisms by varying its type (silica type and structure), silica content, and the polymerfiller coupling agent (organosilanes). This work is expected to bring improvements to the preparation and the experimental evaluation of rubber compounds, by understanding the role of vulcanization and polymer blend morphology for the formation of voids in the polymer matrix and the consequences of these voids for the endurance performance and the energy dissipation in tires.
DOI: 10.6084/m9.figshare.22337065
title: Naturally occurring beneficial bacteria Vibrio alginolyticus X-2 protects seaweed from bleaching disease

description: Microbiome manipulation is gaining fresh attention as a way to mitigate diseases in aquaculture. The commercially farmed seaweed <em>Saccharina japonica</em> suffers from a bacterial induced bleaching disease that has major implications for the reliable supply of healthy sporelings. Here, we identify a beneficial bacterium, <em>Vibrio alginolyticus</em> X-2 that significantly decreases bleaching disease risk. By combining infection assays and multi-omic analyses, we provide evidence to suggest that the underlying protection mechanisms of <em>V. alginolyticus</em> X-2 involves maintaining epibacterial communities, increasing the expression of <em>S. japonica</em> genes related to immune and stress protection pathways and stimulating betaine concentrations in <em>S. japonica </em>holoboints. Thus, <em>V. alginolyticus</em> X-2 can elicit a suite of microbial and host responses to mitigate the bleaching disease. Our study provided insights into disease control in farmed <em>S. japonica</em> though the application of beneficial bacterium.
DOI: 10.6084/m9.figshare.22337065.v4
title: Naturally occurring beneficial bacteria Vibrio alginolyticus X-2 protects seaweed from bleaching disease

description: Microbiome manipulation is gaining fresh attention as a way to mitigate diseases in aquaculture. The commercially farmed seaweed <em>Saccharina japonica</em> suffers from a bacterial induced bleaching disease that has major implications for the reliable supply of healthy sporelings. Here, we identify a beneficial bacterium, <em>Vibrio alginolyticus</em> X-2 that significantly decreases bleaching disease risk. By combining infection assays and multi-omic analyses, we provide evidence to suggest that the underlying protection mechanisms of <em>V. alginolyticus</em> X-2 involves maintaining epibacterial communities, increasing the expression of <em>S. japonica</em> genes related to immune and stress protection pathways and stimulating betaine concentrations in <em>S. japonica </em>holoboints. Thus, <em>V. alginolyticus</em> X-2 can elicit a suite of microbial and host responses to mitigate the bleaching disease. Our study provided insights into disease control in farmed <em>S. japonica</em> though the application of beneficial bacterium.
DOI: 10.6084/m9.figshare.22337065.v3
title: Naturally occurring beneficial bacteria Vibrio alginolyticus X-2 protects seaweed from bleaching disease

description: Microbiome manipulation is gaining fresh attention as a way to mitigate diseases in aquaculture. The commercially farmed seaweed <em>Saccharina japonica</em> suffers from a bacterial induced bleaching disease that has major implications for the reliable supply of healthy sporelings. Here, we identify a beneficial bacterium, <em>Vibrio alginolyticus</em> X-2 that significantly decreases bleaching disease risk. By combining infection assays and multi-omic analyses, we provide evidence to suggest that the underlying protection mechanisms of <em>V. alginolyticus</em> X-2 involves maintaining epibacterial communities, increasing the expression of <em>S. japonica</em> genes related to immune and stress protection pathways and stimulating betaine concentrations in <em>S. japonica </em>holoboints. Thus, <em>V. alginolyticus</em> X-2 can elicit a suite of microbial and host responses to mitigate the bleaching disease. Our study provided insights into disease control in farmed <em>S. japonica</em> though the application of beneficial bacterium.
DOI: 10.6084/m9.figshare.20449401.v1
title: DNA barcode datasets

description: Raw data for "Global convergence of dominance and neglect in flying insect diversity"
DOI: 10.6084/m9.figshare.20449401
title: DNA barcode datasets

description: Raw data for "Global convergence of dominance and neglect in flying insect diversity"
DOI: 10.6084/m9.figshare.22094465.v1
title: Solar-driven Efficient Heterogeneous Subminute Water Disinfection Nanosystem Assembled with Fingerprint MoS2

description: Here, we successfully address the aforementioned issues of heterogeneous disinfection by developing discrete nanoflakes of (Al2O3@v-MoS2)/Cu/Fe3O4 in which vertically aligned 2-D nanofingerprint MoS2 is hybridized with Cu metal and magnetic Fe3O4 particles. Three exciting features are integrated into such a novel structure: bifacial vertically aligned MoS2 grown on the top and bottom surfaces of light-transparent Al2O3 nanoflakes that can absorb not only UV light but also almost the full spectrum of visible light, and both sides can operate simultaneously; a Cu-MoS2 junction that enhances charge separation for the efficient generation of reactive oxygen species (ROS); and magnetic Fe3O4 nanoparticles that have magnetic separation capability and conveniently regenerate after disinfection. The (Al2O3@v-MoS2)/Cu/Fe3O4 nanostructures reported herein exhibit outstanding water disinfection with thorough inactivation of over 5.7 log10 CFU ml-1 E. coli within 1 minute in real sunlight (the system thermal effect has little impact on disinfection performances) and with facile separation and reuse, demonstrating broad application prospects.
DOI: 10.6084/m9.figshare.22094465
title: Solar-driven Efficient Heterogeneous Subminute Water Disinfection Nanosystem Assembled with Fingerprint MoS2

description: Here, we successfully address the aforementioned issues of heterogeneous disinfection by developing discrete nanoflakes of (Al2O3@v-MoS2)/Cu/Fe3O4 in which vertically aligned 2-D nanofingerprint MoS2 is hybridized with Cu metal and magnetic Fe3O4 particles. Three exciting features are integrated into such a novel structure: bifacial vertically aligned MoS2 grown on the top and bottom surfaces of light-transparent Al2O3 nanoflakes that can absorb not only UV light but also almost the full spectrum of visible light, and both sides can operate simultaneously; a Cu-MoS2 junction that enhances charge separation for the efficient generation of reactive oxygen species (ROS); and magnetic Fe3O4 nanoparticles that have magnetic separation capability and conveniently regenerate after disinfection. The (Al2O3@v-MoS2)/Cu/Fe3O4 nanostructures reported herein exhibit outstanding water disinfection with thorough inactivation of over 5.7 log10 CFU ml-1 E. coli within 1 minute in real sunlight (the system thermal effect has little impact on disinfection performances) and with facile separation and reuse, demonstrating broad application prospects.
DOI: 10.6084/m9.figshare.22272259.v1
title: On the behavior of spin-orbit connection of exoplanets

description: List of 1055 selected TOI and KOI main-sequence stars. The following information is listed: the TIC and KIC ID, TOI and KOI ID, status of planet detection, rotation period (Prot), planetary orbital period (Porb), planet radius, semi-major axis, and stellar mass.
DOI: 10.6084/m9.figshare.22272259
title: On the behavior of spin-orbit connection of exoplanets

description: List of 1055 selected TOI and KOI main-sequence stars. The following information is listed: the TIC and KIC ID, TOI and KOI ID, status of planet detection, rotation period (Prot), planetary orbital period (Porb), planet radius, semi-major axis, and stellar mass.
DOI: 10.5281/zenodo.7926141
title: SpliceAI_rocksdb_hg38_chr7

description: SpliceAI RocksDB for chromosome 7 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7926140
title: SpliceAI_rocksdb_hg38_chr7

description: SpliceAI RocksDB for chromosome 7 of hg38 as used in the AbSplice publication: https://www.nature.com/articles/s41588-023-01373-3 Precomputed SpliceAI scores for all SNVs and indels up to 4 nucleotides are stored in this database. To use this database for fast computation of SpliceAI predictions see: https://github.com/gagneurlab/spliceai_rocksdb This is also implemented in the AbSplice package: https://github.com/gagneurlab/absplice This dataset includes SpliceAI scores. The scores are free for academic and not-for-profit use; other use requires a commercial license from Illumina, Inc., see the GitHub repository of SpliceAI: https://github.com/Illumina/SpliceAI/tree/master
DOI: 10.5281/zenodo.7404653
title: Mycenean Linear B sequences - series D

description: We present a dataset for Symbol-level language modelling of linear B scripts using a Bidirectional Recurrent Neural Network. <br> The RNN is trained to predict the missing symbol in a given Mycenaean sequence. It includes Series "D" sequences 2565 sequences without missing symbols extracted from: <br> J. Chadwick, L. Godart, J. T. Killen, J. P. Olivier, A. Sacconi, and I. A. Sakellarakis. Corpus of Mycenaean Inscriptions from Knossos: Volumes 1-4, Cambridge University Press, 1987.<br> <br> The first 513 sequences result from the processing of series D tablets,<br> The next 725 sequences result from the augmentation techniques described in the paper<br> The remaining 1327 sequences are duplicates to minimize bias. The dataset was used in the following publication: <br> K. PAPAVASSILEIOU, Kosmopoulos, D. I., G. Owens, “A generative model for the Mycenaean Linear B script and its application in infilling text from ancient tablets”, ACM Journal on Computing and Cultural Heritage, https://doi.org/10.1145/3593431. If you use this dataset please cite this publication.
DOI: 10.5281/zenodo.7404652
title: Mycenean Linear B sequences - series D

description: We present a dataset for Symbol-level language modelling of linear B scripts using a Bidirectional Recurrent Neural Network. <br> The RNN is trained to predict the missing symbol in a given Mycenaean sequence. It includes Series "D" sequences 2565 sequences without missing symbols extracted from: <br> J. Chadwick, L. Godart, J. T. Killen, J. P. Olivier, A. Sacconi, and I. A. Sakellarakis. Corpus of Mycenaean Inscriptions from Knossos: Volumes 1-4, Cambridge University Press, 1987.<br> <br> The first 513 sequences result from the processing of series D tablets,<br> The next 725 sequences result from the augmentation techniques described in the paper<br> The remaining 1327 sequences are duplicates to minimize bias. The dataset was used in the following publication: <br> K. PAPAVASSILEIOU, Kosmopoulos, D. I., G. Owens, “A generative model for the Mycenaean Linear B script and its application in infilling text from ancient tablets”, ACM Journal on Computing and Cultural Heritage, https://doi.org/10.1145/3593431. If you use this dataset please cite this publication.